Biomarkers in Alzheimer’s Disease: Are Olfactory Neuronal Precursors Useful for Antemortem Biomarker Research?

Author:

Santillán-Morales Valeria1ORCID,Rodriguez-Espinosa Norberto23ORCID,Muñoz-Estrada Jesús4ORCID,Alarcón-Elizalde Salvador1,Acebes Ángel5,Benítez-King Gloria1ORCID

Affiliation:

1. Laboratory of Neuropharmacology, Clinical Research, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 14370, Mexico

2. Department of Neurology, University Hospital Nuestra Señora de Candelaria, 38010 Tenerife, Spain

3. Department of Internal Medicine, Dermatology and Psychiatry, Faculty of Health Sciences, University of La Laguna (ULL), 38200 Tenerife, Spain

4. Department of Computational Biomedicine, Cedars Sinai Medical Center, Los Angeles, CA 90069, USA

5. Department of Basic Medical Sciences, Institute of Biomedical Technologies (ITB), University of La Laguna (ULL), 38200 Tenerife, Spain

Abstract

Alzheimer’s disease (AD), as the main cause of dementia, affects millions of people around the world, whose diagnosis is based mainly on clinical criteria. Unfortunately, the diagnosis is obtained very late, when the neurodegenerative damage is significant for most patients. Therefore, the exhaustive study of biomarkers is indispensable for diagnostic, prognostic, and even follow-up support. AD is a multifactorial disease, and knowing its underlying pathological mechanisms is crucial to propose new and valuable biomarkers. In this review, we summarize some of the main biomarkers described in AD, which have been evaluated mainly by imaging studies in cerebrospinal fluid and blood samples. Furthermore, we describe and propose neuronal precursors derived from the olfactory neuroepithelium as a potential resource to evaluate some of the widely known biomarkers of AD and to gear toward searching for new biomarkers. These neuronal lineage cells, which can be obtained directly from patients through a non-invasive and outpatient procedure, display several characteristics that validate them as a surrogate model to study the central nervous system, allowing the analysis of AD pathophysiological processes. Moreover, the ease of obtaining and harvesting endows them as an accessible and powerful resource to evaluate biomarkers in clinical practice.

Funder

Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

Institute of Biomedical Technologies

Spanish AEI Grant

Publisher

MDPI AG

Subject

General Neuroscience

Reference184 articles.

1. Gauthier, S., Webster, C., Servaes, S., Morais, J., and Rosa-Neto, P. (2022). World Alzheimer Report 2022—Life after Diagnosis: Navigating Treatment, Care and Support, Alzheimer’s Disease International.

2. (2023). 2023 Alzheimer’s Disease Facts and Figures, John Wiley and Sons Inc.

3. American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association.

4. The Diagnosis of Dementia Due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease;McKhann;Alzheimers Dement.,2011

5. Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework;Atkinson;Clin. Pharmacol. Ther.,2001

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2023 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3